Diane G. Gerst
Known title: DirectorCIK: 0001611283
Associated companies
Transaction History
| AMPH | ▲ Buy | Grant | 8,143 | $0 | 6/1/2026 | View on chart |
| AMPH | ▲ Buy | Grant | 5,122 | $0 | 6/2/2025 | View on chart |
| AMPH | ▲ Buy | Grant | 3,076 | $0 | 6/3/2024 | View on chart |
| AMPH | ▲ Buy | Grant | 2,716 | $0 | 6/5/2023 | View on chart |
| AMPH | ▼ Sell | Open Market | 1,520 | $57K | 7/18/2022 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 1,520 | $31K | 7/18/2022 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 1,521 | $31K | 7/11/2022 | View on chart |
| AMPH | ▼ Sell | Open Market | 1,521 | $55K | 7/11/2022 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 1,813 | $36K | 7/5/2022 | View on chart |
| AMPH | ▼ Sell | Open Market | 1,813 | $63K | 7/5/2022 | View on chart |
| AMPH | ▼ Sell | Open Market | 5,146 | $180K | 6/30/2022 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 3,333 | $67K | 6/30/2022 | View on chart |
| AMPH | ▲ Buy | Option Exercise | 1,813 | $36K | 6/30/2022 | View on chart |
| AMPH | ▲ Buy | Grant | 4,163 | $0 | 6/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Amphastar (AMPH) Cited as Safe-and-Steady Stock in Yahoo Analysis
A recent Yahoo Finance article highlighted Amphastar Pharmaceuticals as a 'safe-and-steady' stock worth researching further. This positive framing contrasts with other companies facing challenges, suggesting the market views AMPH as a relatively stable option. The stock currently trades with a trailing P/E of 14.2, which is lower than the average analyst target price of $22.50.
Amphastar (AMPH) Cited as Safe-and-Steady Stock in Yahoo Analysis. A recent Yahoo Finance article highlighted Amphastar Pharmaceuticals as a 'safe-and-steady' stock worth researching further. This positive framing contrasts with other companies facing challenges, suggesting the market views AMPH as a relatively stable option. The stock currently trades with a trailing P/E of 14.2, which is lower than the average analyst target price of $22.50.